$GERN
GERON CORP

2024 Q1 Form 10-K Financial Statement

#000095017024022056 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $304.0K $23.00K $237.0K
YoY Change 1347.62% -77.67% -60.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $27.07M $21.40M $69.14M
YoY Change 109.9% 54.59% 58.46%
% of Gross Profit
Research & Development $29.37M $32.91M $125.0M
YoY Change 7.91% 16.66% 30.91%
% of Gross Profit
Depreciation & Amortization $111.0K $114.0K $442.0K
YoY Change 12.12% 42.5% 53.47%
% of Gross Profit
Operating Expenses $56.44M $54.31M $194.2M
YoY Change 40.7% 29.15% 39.55%
Operating Profit -$56.13M -$193.9M
YoY Change 40.01% 39.98%
Interest Expense $3.433M $2.275M $8.312M
YoY Change 78.62% -395.45% 20.78%
% of Operating Profit
Other Income/Expense, Net -$62.00K $41.00K -$23.00K
YoY Change -258.97% -52.33% -102.3%
Pretax Income -$55.39M -$51.97M -$184.1M
YoY Change 45.3% 21.9% 29.76%
Income Tax
% Of Pretax Income
Net Earnings -$55.39M -$51.97M -$184.1M
YoY Change 45.3% 21.9% 29.76%
Net Earnings / Revenue -18220.39% -225969.57% -77690.72%
Basic Earnings Per Share -$0.09 -$0.32
Diluted Earnings Per Share -$0.09 -$0.09 -$0.32
COMMON SHARES
Basic Shares Outstanding 546.1M 543.1M 570.6M
Diluted Shares Outstanding 603.5M 570.6M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $443.0M $333.7M $333.7M
YoY Change 16.36% 93.17% 93.17%
Cash & Equivalents $189.8M $70.02M $70.02M
Short-Term Investments $253.3M $263.7M $263.7M
Other Short-Term Assets $6.831M $5.994M $5.994M
YoY Change 45.77% 37.6% 37.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $451.5M $341.3M $341.3M
YoY Change 16.66% 89.38% 89.38%
LONG-TERM ASSETS
Property, Plant & Equipment $1.681M $1.177M $4.733M
YoY Change 57.69% 48.42% -4.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $20.78M $43.30M $43.30M
YoY Change -26.04%
Other Assets $4.710M $4.697M $4.697M
YoY Change 0.36% -12.84% -12.84%
Total Long-Term Assets $30.57M $52.73M $52.73M
YoY Change -19.26% 410.49% 410.49%
TOTAL ASSETS
Total Short-Term Assets $451.5M $341.3M $341.3M
Total Long-Term Assets $30.57M $52.73M $52.73M
Total Assets $482.1M $394.1M $394.1M
YoY Change 13.46% 106.78% 106.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.992M $6.161M $6.161M
YoY Change 195.36% -39.54% -39.54%
Accrued Expenses $33.89M $40.31M $55.02M
YoY Change -2.31% 21.78% 20.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $71.53M $46.89M $46.89M
YoY Change 123.89% 123.89%
Total Short-Term Liabilities $123.2M $108.1M $108.1M
YoY Change 180.47% 40.91% 40.91%
LONG-TERM LIABILITIES
Long-Term Debt $11.22M $35.05M $35.05M
YoY Change -78.17% 16.02% 16.02%
Other Long-Term Liabilities $2.829M $3.006M $3.006M
YoY Change -19.45% -18.11% -18.11%
Total Long-Term Liabilities $11.22M $35.05M $38.06M
YoY Change -78.17% 16.02% 12.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $123.2M $108.1M $108.1M
Total Long-Term Liabilities $11.22M $35.05M $38.06M
Total Liabilities $134.4M $146.1M $146.1M
YoY Change 40.99% 32.15% 32.15%
SHAREHOLDERS EQUITY
Retained Earnings -$1.653B -$1.598B
YoY Change 13.87% 13.03%
Common Stock $1.998B $1.846B
YoY Change 12.39% 23.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $344.9M $247.9M $247.9M
YoY Change
Total Liabilities & Shareholders Equity $482.1M $394.1M $394.1M
YoY Change 13.46% 106.78% 106.78%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$55.39M -$51.97M -$184.1M
YoY Change 45.3% 21.9% 29.76%
Depreciation, Depletion And Amortization $111.0K $114.0K $442.0K
YoY Change 12.12% 42.5% 53.47%
Cash From Operating Activities -$62.25M -$40.94M -$167.7M
YoY Change 34.27% 16.36% 31.69%
INVESTING ACTIVITIES
Capital Expenditures $615.0K $64.00K $830.0K
YoY Change 65.32% -54.29% 92.58%
Acquisitions
YoY Change
Other Investing Activities $34.82M $47.63M -$179.5M
YoY Change -119.52% 149.02% -387.2%
Cash From Investing Activities $34.21M $47.57M -$180.3M
YoY Change -119.14% 150.52% -390.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 147.8M 33.28M 362.0M
YoY Change -47.41% 179.12% 314.86%
NET CHANGE
Cash From Operating Activities -62.25M -40.94M -167.7M
Cash From Investing Activities 34.21M 47.57M -180.3M
Cash From Financing Activities 147.8M 33.28M 362.0M
Net Change In Cash 119.7M 39.91M 13.93M
YoY Change 114.08% -1034.68% -36.55%
FREE CASH FLOW
Cash From Operating Activities -$62.25M -$40.94M -$167.7M
Capital Expenditures $615.0K $64.00K $830.0K
Free Cash Flow -$62.87M -$41.00M -$168.6M
YoY Change 34.51% 16.08% 31.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 ecd Trd Arr Duration
TrdArrDuration
P365D
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000886744
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-20859
CY2023 dei Entity Registrant Name
EntityRegistrantName
GERON CORP
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-2287752
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
919 East Hillsdale Blvd.
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
473-7700
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
GERN
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
1394546000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
546059309
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Jose, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70023000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56845000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1115000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
364000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
263676000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
115901000
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1655000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
3144000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4879000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3992000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
341348000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
180246000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
43298000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1177000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
793000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3556000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4147000
CY2023Q4 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
4697000
CY2022Q4 gern Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
5389000
CY2023Q4 us-gaap Assets
Assets
394076000
CY2022Q4 us-gaap Assets
Assets
190575000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6161000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10190000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13759000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11534000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
949000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
925000
CY2023Q4 us-gaap Debt Current
DebtCurrent
46893000
CY2022Q4 us-gaap Debt Current
DebtCurrent
20945000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40308000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33100000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
108070000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
76694000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3006000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3671000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35051000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30212000
CY2023Q4 us-gaap Liabilities
Liabilities
146127000
CY2022Q4 us-gaap Liabilities
Liabilities
110577000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1350000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1350000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
544912215
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
544912215
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
390262524
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
390262524
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
545000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
390000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1844988000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1493469000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1597769000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1413642000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
185000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
247949000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79998000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394076000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
190575000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
237000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
596000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1393000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
125046000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
95518000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
85727000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
69135000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43628000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29665000
CY2023 us-gaap Operating Expenses
OperatingExpenses
194181000
CY2022 us-gaap Operating Expenses
OperatingExpenses
139146000
CY2021 us-gaap Operating Expenses
OperatingExpenses
115392000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-193944000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-138550000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-113999000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
18152000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
2529000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
527000
CY2023 us-gaap Interest Expense
InterestExpense
8312000
CY2022 us-gaap Interest Expense
InterestExpense
6882000
CY2021 us-gaap Interest Expense
InterestExpense
3740000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1002000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1100000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-184127000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-141901000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-116112000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
570645405
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
570645405
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
380784846
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
380784846
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
327631814
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
327631814
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-184127000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-141901000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-116112000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
431000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-251000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-183723000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141947000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116363000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
210947000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-116112000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-251000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20385000
CY2021 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
2479000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
91000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
797000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8080000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
126416000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-141901000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-68000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
22000
CY2022 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
69916000
CY2022 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
15163000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
264000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2185000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8001000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79998000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-184127000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
431000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2023 gern Public Offering Stock Issued During Period Value New Issue
PublicOfferingStockIssuedDuringPeriodValueNewIssue
213337000
CY2023 gern Issuance Of Common Stock In Connection With Warrant Exercise Value
IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
105912000
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
829000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13070000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18526000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
247949000
CY2023 us-gaap Profit Loss
ProfitLoss
-184127000
CY2022 us-gaap Profit Loss
ProfitLoss
-141901000
CY2021 us-gaap Profit Loss
ProfitLoss
-116112000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
442000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
288000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
215000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11150000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
965000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1424000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1088000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1327000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
893000
CY2021 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
1233000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
828000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
264000
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
91000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
18526000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
8001000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
8080000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
591000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
580000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
568000
CY2023 gern Increase Decrease In Accrued Interest Receivable Net And Other Receivables
IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
-1490000
CY2022 gern Increase Decrease In Accrued Interest Receivable Net And Other Receivables
IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
1381000
CY2021 gern Increase Decrease In Accrued Interest Receivable Net And Other Receivables
IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
1041000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
886000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2630000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1317000
CY2023 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-692000
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
594000
CY2021 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
3807000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4029000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3503000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2224000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3435000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-119000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
7208000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3266000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
14909000
CY2023 gern Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-640000
CY2022 gern Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-572000
CY2021 gern Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-509000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-167743000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127379000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95556000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
830000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
431000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
475594000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
258007000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
177434000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
296102000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
320505000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
247994000
CY2021 us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
1594000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180322000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
62067000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
71947000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
13072000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2185000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
797000
CY2023 gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
213337000
CY2022 gern Proceeds From Public Offering Issuance Of Common Stock And Warrants
ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
69916000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20385000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
105912000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
15163000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2479000
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
29700000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
24895000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
362021000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87264000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48556000
CY2023 gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-27000
CY2022 gern Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13929000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21974000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24947000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57209000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35235000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10288000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71138000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57209000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35235000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P4Y
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16815000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
16815000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1115000
CY2023Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
1115000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306784000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
402000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
212000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306974000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
39771000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39771000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
364000
CY2022Q4 us-gaap Restricted Investments At Fair Value
RestrictedInvestmentsAtFairValue
364000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
116142000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
247000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
115901000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
166518000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
211000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
166518000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
211000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
75721000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
165000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
28435000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
82000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
104156000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
247000
CY2007Q4 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
13842625
CY2020Q3 us-gaap Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method
BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod
we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of 35,990,825 shares of BARD1.
CY2020Q3 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
35990825
CY2021Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1233000
CY2021Q1 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
0
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2408000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1689000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1231000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
896000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1177000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
793000
CY2023Q4 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
23541000
CY2022Q4 gern Accrued Clinical Research Organizations And Clinical Trial Costs Current
AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
17040000
CY2023Q4 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
14629000
CY2022Q4 gern Accrued Manufacturing Activities Current
AccruedManufacturingActivitiesCurrent
5321000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9668000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
768000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
561000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
814000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
510000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40308000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33100000
CY2023Q4 gern Litigation Settlement Amount Outstanding
LitigationSettlementAmountOutstanding
0
CY2023 gern Number Of Severance Plan
NumberOfSeverancePlan
2
CY2023 gern Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period
LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod
P12M
CY2023 gern Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity
LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity
P30D
CY2023 gern Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment
LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment
P12M
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
962000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
944000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
946000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
344000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
310000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
252000
CY2023 us-gaap Lease Cost
LeaseCost
1306000
CY2022 us-gaap Lease Cost
LeaseCost
1254000
CY2021 us-gaap Lease Cost
LeaseCost
1198000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
56066000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
39262000
CY2023Q4 gern Long Term Debt Gross
LongTermDebtGross
95328000
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
10088000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
605000
CY2023Q4 gern Debt Instrument Unamortized End Of Term Charge
DebtInstrumentUnamortizedEndOfTermCharge
2691000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
46893000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35051000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1350000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
18370729
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
65902400
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.87
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
56368058
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20855230
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20855230
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.72
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
36864
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8869302
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.39
CY2023 gern Share Based Compensation Forfeitures And Expirations In Period Net
ShareBasedCompensationForfeituresAndExpirationsInPeriodNet
4903977
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4903977
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.15
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
58750670
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
72984351
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.16
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25391643
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
39995642
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.16
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M10D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15557976
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
71983176
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.15
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M1D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
25169074
CY2023Q4 us-gaap Share Price
SharePrice
2.11
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
39995642
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
36085389
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
30459136
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.16
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.17
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.35
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11986000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
787000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
93000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12356000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1799000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
556000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18525000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8001000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8080000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
37628000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P26M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
72984351
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
58750670
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53904980
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
186385839
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.066
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.068
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.09
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.041
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.049
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.057
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.012
CY2023 gern Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted
EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
-0.057
CY2022 gern Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted
EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
-0.043
CY2021 gern Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted
EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
-0.054
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.248
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.275
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.289
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
272300000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
254500000
CY2023Q4 gern Deferred Tax Assets Federal And State Credits
DeferredTaxAssetsFederalAndStateCredits
64700000
CY2022Q4 gern Deferred Tax Assets Federal And State Credits
DeferredTaxAssetsFederalAndStateCredits
56700000
CY2023Q4 gern Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
43300000
CY2022Q4 gern Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
21800000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11200000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
10800000
CY2023Q4 gern Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1100000
CY2022Q4 gern Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1300000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3600000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5600000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
396200000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
350700000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
395200000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
349600000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1000000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1100000
CY2023Q4 gern Deferred Tax Liabilities Operating Leases Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
1000000
CY2022Q4 gern Deferred Tax Liabilities Operating Leases Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
1100000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1000000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1100000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
45600000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
38900000
CY2022 gern Employer Tax Receivable
EmployerTaxReceivable
483000
CY2021 gern Employer Tax Receivable
EmployerTaxReceivable
1100000
CY2023Q4 gern Employee Retention Credit Amount Outstanding Receivables
EmployeeRetentionCreditAmountOutstandingReceivables
0
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
26300000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23700000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2600000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
26300000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-431000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-68000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-251000
CY2022 gern Reclassification Between Prepaid And Other Current Assets And Deposits And Other Assets
ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets
-5000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
-7017000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5154000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2704000
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Trd Arr Ind Name
TrdArrIndName
Faye Feller, M.D.
CY2023Q4 ecd Trd Arr Ind Title
TrdArrIndTitle
ExecutiveVice President and Chief Medical Officer
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
true
CY2023Q4 ecd Trd Arr Termination Date
TrdArrTerminationDate
October 25, 2023
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023Q4 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
30000
CY2023Q4 gern Trd Arr Expiration Date
TrdArrExpirationDate
January 12, 2024
CY2023Q4 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
January 13, 2023

Files In Submission

Name View Source Status
0000950170-24-022056-index-headers.html Edgar Link pending
0000950170-24-022056-index.html Edgar Link pending
0000950170-24-022056.txt Edgar Link pending
0000950170-24-022056-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gern-20231231.htm Edgar Link pending
gern-20231231.xsd Edgar Link pending
gern-ex10_23.htm Edgar Link pending
gern-ex10_30.htm Edgar Link pending
gern-ex10_39.htm Edgar Link pending
gern-ex21_1.htm Edgar Link pending
gern-ex23_1.htm Edgar Link pending
gern-ex31_1.htm Edgar Link pending
gern-ex31_2.htm Edgar Link pending
gern-ex32_1.htm Edgar Link pending
gern-ex32_2.htm Edgar Link pending
gern-ex4_1.htm Edgar Link pending
gern-ex97_1.htm Edgar Link pending
img43612817_0.jpg Edgar Link pending
img43612817_1.jpg Edgar Link pending
img43612817_2.jpg Edgar Link pending
img43612817_3.jpg Edgar Link pending
img43612817_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
gern-20231231_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable